DDInter156 DDInter1376
Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Azilsartan medoxomil {u} (Compound) resembles {v} (Compound) Tasosartan
Azilsartan medoxomil {u} (Compound) binds {v} (Gene) AGTR1
Azilsartan medoxomil {u} (Compound) is included by {v} (Pharmacologic Class) Angiotensin 2 Type 1 Receptor Antagonists
Azilsartan medoxomil {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Azilsartan medoxomil {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Azilsartan medoxomil {u} may lead to a major life threatening interaction when taken with {v} Potassium gluconate
Azilsartan medoxomil (Compound) resembles Tasosartan (Compound)
Azilsartan medoxomil (Compound) binds AGTR1 (Gene)
Azilsartan medoxomil (Compound) is included by Angiotensin 2 Type 1 Receptor Antagonists (Pharmacologic Class)
Azilsartan medoxomil (Compound) causes Hyperuricaemia (Side Effect)
Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Azilsartan medoxomil may lead to a major life threatening interaction when taken with Potassium chloride
Azilsartan medoxomil may lead to a major life threatening interaction when taken with Potassium gluconate